; generic drugs (1) In general With respect to the modification of the labeling sought through a supplemental application pursuant to subsection (f)(2)(C) the manufacturer of any generic version shall, by reason of the statement of the Secretary under subsection (d)(2), be deemed to have the same conditions of use and the same labeling as a reference drug for purposes of clauses (i) and (v) of section 505(j)(2)(A). The approval of a supplemental application shall not have any legal effects for the applicant that are different than the legal effects that would have resulted if the supplemental application had been submitted to conform the labeling of the generic version to a change in the labeling of the reference drug. (2) Supplemental applications Changes to labeling made in accordance with this paragraph shall not be eligible for an exclusivity period under this Act. (i) Drug product classes In the case of a selected drug for which the statement of the Secretary under subsection (d)(2) applies to the selected drug as a class of drugs, a supplemental application pursuant to subsection (f)(2)(C) may be submitted for each such drug product. (j) Rule of construction This section shall not be construed as altering the applicability of any substantive approval standard under section 505. (k) Reports Not later than 4 years after the date of the enactment of the Making Objective Drug Evidence Revisions for New Labeling Act and every 4 years thereafter, the Secretary shall prepare and submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, a report that describes the actions of the Secretary under this section and that provides any recommendations of the Secretary for modifying the program under this section, including any recommendations on whether the program should apply to a broader scope of drugs. Each report under this subsection shall be made publicly available on the Internet website of the Food and Drug